Urologists are primed to acquire the knowledge to use targeted agents and immuno-oncologic (IO) therapies for the treatment of advanced and metastatic renal cell carcinoma (RCC). Toxicities are manageable given appropriate patient/caregiver education, on-call and nursing support, and multi-disciplinary care with consulting specialists.
- UroToday Home
- Center Of Excellence
Centers of Excellence
Advanced Kidney Cancer
Curated by clinicians: educational forums with videos, abstracts and conference information
RCC at ASCO 2019: Immunotherapy for Sarcomatoid Disease
I still remember the debates around treating sarcomatoid renal cell carcinoma (RCC) a decade ago when I started in practice. There were not many studies to cite – one that often came up was Naomi Haas’s trial of doxorubicin with gemcitabine (ECOG 8802). The study showed progression-free survival (PFS) of 3.5 months and overall survival (OS) of 8.8 months – sobering results, but at least an option we could pursue in the clinic. I only treated a handful of patients with this regimen, but it was certainly no walk in the park – massive fatigue, cytopenias and a range of other toxicities.
Sumanta (Monty) Kumar Pal, MD, is an internationally recognized leader in the area of genitourinary cancers, including kidney, bladder, and prostate cancer. He is the Co-director of City of Hope's Kidney Cancer Program and is the head of the kidney and bladder cancer disease. Dr. Pal sits on the Editorial Board for clinical genitourinary cancer and is a reviewer for multiple journals including The Journal of Clinical Oncology, The Journal of Urology, European Urology, and many others.
Everyday Urology - Oncology Insights
Publications focusing on urologic cancer treatments through original manuscripts
How I Manage First-Line Therapy for Advanced Kidney Cancer
Library Resources
Evidence based monographs by experts to define and guide clinical practice
Expert Commentary
Evidence based monographs by experts to define and guide clinical practice
Outcomes of Patients with Renal Carcinoma and Sarcomatoid Dedifferentiation Treated with Nephrectomy and Systemic Therapies: Comparison between the Cytokine and Targeted Therapy Eras: Expert Commentary
Written by Zhamshid Okhunov, MD
Department of Urology, University of California, Irvine Urology
Though nephrectomy is the gold standard treatment for renal cell carcinoma, 20%-40% of patients have a recurrence and 20-30% of patients present with metastatic disease1.
When Partial Nephrectomy Is Unsuccessful: Understanding the Reasons for Conversion From Robotic Partial to Radical Nephrectomy at a Tertiary Referral Center - Expert Commentary
Written by Zhamshid Okhunov, MD
Department of Urology, University of California, Irvine Urology
Partial nephrectomies are the standard of care with treatment of T1a or T1b tumors due to their better functional outcomes and decrease cardiovascular morbidity.
A Multicentered, Propensity Matched Analysis Comparing Laparoscopic and Open Surgery for pT3a Renal Cell Carcinoma: Expert Commentary
Written by Zhamshid Okhunov, MD
Department of Urology, University of California, Irvine Urology
Laparoscopic renal surgery (LRS) has long been recognized for its improvements over open renal surgery for patient quality of life.
Conference Coverage
Recent data from conferences worldwide
E-Newsletters
Free Daily and Weekly newsletters offered by content of interest
The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.